Licencing Agreement to Further Preclinical Disease Modelling
Jun 16 2019 Read 303 Times
Danish life sciences business Bioneer A/S, has been granted access to ERS Genomics’ CRISPR/Cas9 genome editing technology intellectual property, to generate a range of human cell based disease models.
The licensing agreement, will enable Hørsholm-based Bioneer to generate and commercialise CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.
Eric Rhodes, CEO of ERS Genomics, said: “Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."
“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.” stated Lars H. Pedersen, CEO of Bioneer. Company CSO Christian Clausen added “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models.”
Financial details of the agreement were not disclosed.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Chromatography - Vacuum Ultraviolet Spectroscopy: A Versatile Tool for Analysis of Gasoline and Jet Fuels - High-performance Columns and Bulk for your Chromatography - New L...
View all digital editions
Oct 22 2019 Cologne, Germany
Oct 22 2019 New York, USA
Oct 23 2019 Beijing, China
Oct 30 2019 Birmingham, UK
Nov 03 2019 Toronto, Canada